Both mechanistic and genetic evidence suggest that Gal1 acts as a positive modifier that is associated with a worse progression of HRAS mutant cancers, notably head and neck cancers that are frequently associated with high Gal1 levels (Supplementary Fig. 2a). The gene discussed is LGALS1; the disease is cancer.